| Assessing the accuracy and reliability of AI-generated medical responses: an evaluation of the Chat-GPT model D Johnson, R Goodman, J Patrinely, C Stone, E Zimmerman, R Donald, ... Research square, 2023 | 200 | 2023 |
| Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L) 1 monotherapy: a multicentre, retrospective, cohort study IP da Silva, T Ahmed, ILM Reijers, AM Weppler, AB Warner, JR Patrinely, ... The Lancet Oncology 22 (6), 836-847, 2021 | 133 | 2021 |
| Chronic immune-related adverse events following adjuvant anti–PD-1 therapy for high-risk resected melanoma JR Patrinely, R Johnson, AR Lawless, P Bhave, A Sawyers, M Dimitrova, ... JAMA oncology 7 (5), 744-748, 2021 | 125 | 2021 |
| Using machine learning algorithms to predict immunotherapy response in patients with advanced melanoma P Johannet, N Coudray, DM Donnelly, G Jour, I Illa-Bochaca, Y Xia, ... Clinical Cancer Research 27 (1), 131-140, 2021 | 112 | 2021 |
| Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research DB Johnson, KL Reynolds, RJ Sullivan, JM Balko, JR Patrinely, ... The Lancet Oncology 21 (8), e398-e404, 2020 | 86 | 2020 |
| Risk factors for intraoperative and postoperative cerebrospinal fluid leaks in endoscopic transsphenoidal sellar surgery PN Patel, AM Stafford, JR Patrinely, DK Smith, JH Turner, PT Russell, ... Otolaryngology–Head and Neck Surgery 158 (5), 952-960, 2018 | 59 | 2018 |
| Lessons from operations management to combat the COVID-19 pandemic JR Patrinley, ST Berkowitz, D Zakria, DJ Totten, M Kurtulus, BC Drolet Journal of Medical Systems 44, 1-2, 2020 | 52 | 2020 |
| Survivorship in immune therapy: assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death … JR Patrinely Jr, AC Young, H Quach, GR Williams, F Ye, R Fan, L Horn, ... European journal of cancer 135, 211-220, 2020 | 50 | 2020 |
| Accuracy and reliability of chatbot responses to physician questions RS Goodman, JR Patrinely, CA Stone, E Zimmerman, RR Donald, ... JAMA network open 6 (10), e2336483-e2336483, 2023 | 45 | 2023 |
| On the cusp: Considering the impact of artificial intelligence language models in healthcare RS Goodman, JR Patrinely Jr, T Osterman, L Wheless, DB Johnson Med 4 (3), 139-140, 2023 | 44 | 2023 |
| Clinical characteristics, disease course, and outcomes of patients with acute generalized exanthematous pustulosis in the US A Creadore, S Desai, A Alloo, AK Dewan, M Bakhtiar, C Cruz-Diaz, ... JAMA dermatology 158 (2), 176-183, 2022 | 42 | 2022 |
| Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders LJ Brown, A Weppler, P Bhave, C Allayous, JR Patrinely Jr, P Ott, ... Journal for Immunotherapy of Cancer 9 (5), 2021 | 38 | 2021 |
| Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+ PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy. I Pires Da Silva, T Ahmed, S Lo, ILM Reijers, A Weppler, A Betof Warner, ... Journal of Clinical Oncology 38 (15_suppl), 10005-10005, 2020 | 37 | 2020 |
| A multicenter characterization of hepatitis associated with immune checkpoint inhibitors JR Patrinely Jr, B McGuigan, S Chandra, SE Fenton, A Chowdhary, ... Oncoimmunology 10 (1), 1875639, 2021 | 33 | 2021 |
| Outcomes after progression of disease with anti–PD‐1/PD‐L1 therapy for patients with advanced melanoma JR Patrinely Jr, LX Baker, EJ Davis, H Song, F Ye, DB Johnson Cancer 126 (15), 3448-3455, 2020 | 23 | 2020 |
| The role of anti-PD-1/PD-L1 in the treatment of skin cancer JR Patrinely Jr, AK Dewan, DB Johnson BioDrugs 34 (4), 495-503, 2020 | 18 | 2020 |
| COVID-19: the emerging role of medical student involvement JR Patrinely, D Zakria, ST Berkowitz, DB Johnson, DJ Totten Medical Science Educator 30, 1641-1643, 2020 | 17 | 2020 |
| Individual cell motion in healthy human skin microvasculature by reflectance confocal video microscopy I Saknite, Z Zhao, JR Patrinely, M Byrne, M Jagasia, ER Tkaczyk Microcirculation 27 (6), e12621, 2020 | 11 | 2020 |
| Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma RS Goodman, A Lawless, R Woodford, F Fa’ak, A Tipirneni, JR Patrinely, ... JAMA Network Open 6 (8), e2327145-e2327145, 2023 | 9 | 2023 |
| Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study P Serra-Bellver, JM Versluis, HK Oberoi, C Zhou, TD Slattery, Y Khan, ... European Journal of Cancer 176, 121-132, 2022 | 9 | 2022 |
Douglas B JohnsonAssociate Professor of Medicine, Vanderbilt University Medical CenterVerified email at vumc.org
